Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy

Climacteric

Volumn 18, Issue 2, 2015, Pages 219-225

  Salvatore, S ^a   Nappi, R E ^b   Parma, M ^a   Chionna, R ^a   Lagona, F ^a   Zerbinati, N ^c   Ferrero, S ^d   Origoni, M ^a   Candiani, M ^a   Leone Roberti Maggiore, U ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

dyspareunia; Fractional CO2 Laser; menopause; sexual function; sexual intercourse; vaginal dryness; vulvovaginal atrophy

Indexed keywords

ADULT; ARTICLE; CARBON DIOXIDE LASER; DISEASE SEVERITY; DYSPAREUNIA; DYSURIA; FEMALE; FEMALE SEXUAL FUNCTION INDEX; FOLLOW UP; FRACTIONAL MICROABLATIVE CARBON DIOXIDE LASER; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SEXUAL SATISFACTION; SHORT FORM 12; VAGINA ATROPHY; VAGINAL BURNING SENSATION; VAGINAL DRYNESS; VAGINAL PRURITUS; VISUAL ANALOG SCALE; AGED; ATROPHY; GAS LASER; MIDDLE AGED; PATHOLOGY; PATIENT SATISFACTION; PHYSIOLOGY; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; THERAPEUTIC USE; VAGINA; VULVA;

AGED; ATROPHY; FEMALE; HUMANS; LASERS, GAS; MIDDLE AGED; PATIENT SATISFACTION; POSTMENOPAUSE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; VAGINA; VULVA;

EID: 84924662300     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.975197     Document Type: Article

References (50)

1. Mehta A, B achmann G. V ulvovaginal complaints. C lin Obstet Gynecol 2008; 51: 549-55
2. Palacios S. M anaging urogenital atrophy. M aturitas 2 009; 63: 315-18
3. Parish S J, N appi R E, K rychman M L, e t a l. I mpact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013; 5: 437-47
4. Santoro N, K omi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009; 6: 2133-42
5. P astore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women ' s Health Initiative. Maturitas 2004; 49: 292-303
6. Nappi R E, K okot-Kierepa M. W omen ' s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010; 67: 233-8
7. Nappi R E, K okot-Kierepa M. V aginal Health: Insights, Views and Attitudes (VIVA)-results from an international survey. Climacteric 2012; 15: 36-44
8. Nappi R E, K ingsberg S, M aamari R, S imon J. T he CLOSER (Clarifying Vaginal Atrophy's Impact On Sex and Relationships) Survey: Implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med 2013; 10: 2232-41
9. Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009; 63: 138-41
10. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014; 17: 3-9
11. Calleja-Agius J, B rincat M P. U rogenital atrophy. C limacteric 2009; 12: 279-85
12. Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010; 13: 509-22
13. Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning. J Sex Med 2009; 6: 603-16
14. Levine K, Williams R, Harmann K. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008; 15: 661-6
15. Avis NE, Brockwell S, Randolph JF, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. Menopause 2009; 16: 442-52
16. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000; 96: 351-8
17. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril 2001; 76: 456-60
18. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012; 15: 267-74
19. Rees M, P é rez-Ló pez FR, Ceasu I, e t al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas 2012; 73: 171-4
20. NAMS. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013; 20: 888-902
21. de Villiers TJ, P ines A, P anay N, et al. o n behalf of the International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013; 16: 316-37
22. Al-Azzawi F, Bitzer J, Brandenburg U, et al. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric 2010; 13: 103-20
23. Rosenberg SM, Tamimi RM, Gelber S, et al. Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer 2014; 120: 2264-71
24. Ong MW, Bashir SJ. Fractional laser resurfacing for acne scars: a review. Br J Dermatol 2012; 166: 1160-9
25. Tierney EP, Hanke CW. Ablative fractionated CO2, laser resurfacing for the neck: prospective study and review of the literature. J Drugs Dermatol 2009; 8: 723-31
26. Peterson JD, G oldman MP. R ejuvenation of the aging chest: a review and our experience. Dermatol Surg 2011; 37: 555-71
27. Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014; 17: 363-9
28. Ettinger B, Hait H, Reape KZ, Shu H. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 2008; 15: 885-9
29. Bump RC, Mattiasson A, Bo K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic fl oor dysfunction. Am J Obstet Gynecol 1996; 175: 10-17
30. Griesser H, S konietzki S, F ischer T, F ielder K, S uesskind M. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the effi cacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 2012; 71: 360-8
31. Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 2011; 117: 922-7
32. Rosen RC, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191-208
33. Nappi RE, Albani F, Vaccaro P, et al. Use of the Italian translation of the sexual function index (FSFI) in routine gynecological practice. Gynecol Endocrinol 2008; 24: 214-19
34. Filocamo MT, Serati M, Li Marzi V, et al. The Female Sexual Function Index (FSFI): linguistic validation of the Italian version. J Sex Med 2014; 11: 447-53
35. Fernandes T, Costa-Paiva LH, Pinto-Neto AM. Effi cacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. J Sex Med 2014; 11: 1262-70
36. Leone Roberti Maggiore U, A lessandri F, M edica M, G abelli M, Venturini PL, Ferrero S. Periurethral injection of polyacrylamide hydrogel for the treatment of stress urinary incontinence: the impact on female sexual function. J Sex Med 2012; 9: 3255-63
37. Ware J, K osinski M, K eller S D. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-33
38. Checa M A, G arrido A, P rat M, C onangla M, R ueda C, C arreras R. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study. Maturitas 2005; 52: 70-7
39. Bradford A. L istening to placebo in clinical trials for female sexual dysfunction. J Sex Med 2013; 10: 451-9
40. Longo C, G alimberti M, D e Pace B, P ellacani G, B encini P L. Laser skin rejuvenation: epidermal changes and collagen remodeling evaluated by in vivo confocal microscopy. Lasers Med Sci 2013; 28: 769-76
41. Utian W H, M aamari R. A ttitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study. Climacteric 2014; 17: 29-36
42. Nappi R E. N ew attitudes to sexuality in the menopause: clinical evaluation and diagnosis. Climacteric 2007; 10(Suppl 2): 105-8
43. Archer DF. Effi cacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010; 17: 194-203
44. Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt) 2010; 19: 425-32
45. Simon J A. I dentifying and treating sexual dysfunction in postmenopausal women: the role of estrogen. J Womens Health (Larchmt) 2011; 20: 1453-65
46. Salvatore S, Digesu G, Siesto G, et al. Vaginal collagen remodelling after fractional carbon dioxide laser surgery. Presented at Annual Meeting of the International Continence Society, Glasgow, United Kingdom, August-September 2011 [abstract 233]
47. Bachmann G A, L eiblum S R. S exuality in sexagenarian women. Maturitas 1991; 13: 43-50
48. Woloski-Wruble A C, O liel Y, L eefsma M, H ochner-Celnikier D. Sexual activities, sexual and life satisfaction, and successful aging in women. J Sex Med 2010; 7: 2401-10
49. Schneidewind-Skibbe A, Hayes RD, Koochaki PE, Meyer J, Dennerstein L. The frequency of sexual intercourse reported by women: a review of community-based studies and factors limiting their conclusions. J Sex Med 2008; 5: 301-35
50. Nicolosi A, Laumann EO, Glasser DB, Moreira ED Jr, Paik A, Gingell C. Global Study of Sexual Attitudes and Behaviors Investigators ' Group. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology 2004; 64: 991-7